Gsa Capital Partners LLP Revance Therapeutics, Inc. Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 20,819 shares of RVNC stock, worth $53,504. This represents 0.01% of its overall portfolio holdings.
Number of Shares
20,819Holding current value
$53,504% of portfolio
0.01%Shares
12 transactions
Others Institutions Holding RVNC
# of Institutions
230Shares Held
81.5MCall Options Held
617KPut Options Held
870K-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.73MShares$14.7 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA4.78MShares$12.3 Million0.0% of portfolio
-
Fil LTD Hamilton, D04.19MShares$10.8 Million0.01% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ4.16MShares$10.7 Million0.49% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...